Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

Stopped Review of safety and preliminary efficacy data showed marginal anti-tumor activity.

Conditions

• Squamous Non-small Cell Lung Cancer

Interventions

• DRUG: Buparlisib
• DRUG: Buparlisib matching placebo
• DRUG: Docetaxel

Sponsor

Novartis Pharmaceuticals